Secondary analysis of SEAVUE in biologic-naive moderate-to-severe Crohn's disease (adalimumab n=195, ustekinumab n=191): the drugs produced distinct serum protein profiles at weeks 16 and 52; only ustekinumab reduced IL-22.
Secondary analysisn = 386
Venkat et al. Serum protein profiles differ with adalimumab and ustekinumab treatment in moderately to severely active Crohn's disease